Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Narasimha Kumar Karanam"'
Publikováno v:
Advances in Cancer Biology - Metastasis, Vol 7, Iss , Pp 100085- (2023)
The potential role for microRNA (miRNA) in the metastatic process that occurs in head and neck squamous cell carcinoma (HNSCC) was examined. miRNA was extracted from surgically excised tumor samples from 41 HNSCC cancer patients diagnosed with distan
Externí odkaz:
https://doaj.org/article/f688f918ce5a4cd38e841948484745f1
Autor:
Dat T. Vo, Narasimha Kumar Karanam, Lianghao Ding, Debabrata Saha, John S. Yordy, Uma Giri, John V. Heymach, Michael D. Story
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 21, Iss 9, Pp 849-862 (2019)
MicroRNAs (miRNAs) are short single-stranded RNAs, measuring 21 to 23 nucleotides in length and regulate gene expression at the post-transcriptional level through mRNA destabilization or repressing protein synthesis. Dysregulation of miRNAs can lead
Externí odkaz:
https://doaj.org/article/f2ae7aa669de420a930973237dcec1d7
Autor:
Carsten Hagemann, Emil Lou, Michael Story, Chirag B. Patel, Narasimha Kumar Karanam, Kristen W. Carlson, Jack Tuszynski, Kenneth Swanson, Karina Deniz, Ellaine Salvador, Justin C. Moser
Tumor treating fields (TTFields), a new modality of cancer treatment, are electric fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment of glioblastoma multiforme and mesothelioma, and they are currently under s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d98b2d828fe44f3f519b4b7ded69fa6
https://doi.org/10.1158/0008-5472.c.6513993.v1
https://doi.org/10.1158/0008-5472.c.6513993.v1
Autor:
Carsten Hagemann, Emil Lou, Michael Story, Chirag B. Patel, Narasimha Kumar Karanam, Kristen W. Carlson, Jack Tuszynski, Kenneth Swanson, Karina Deniz, Ellaine Salvador, Justin C. Moser
Supplementary Figure from The Mechanisms of Action of Tumor Treating Fields
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02c9e0120153bb402687874361f05bff
https://doi.org/10.1158/0008-5472.22431801
https://doi.org/10.1158/0008-5472.22431801
Autor:
Justin C. Moser, Ellaine Salvador, Karina Deniz, Kenneth Swanson, Jack Tuszynski, Kristen W. Carlson, Narasimha Kumar Karanam, Chirag B. Patel, Michael Story, Emil Lou, Carsten Hagemann
Publikováno v:
Cancer research. 82(20)
Tumor treating fields (TTFields), a new modality of cancer treatment, are electric fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment of glioblastoma multiforme and mesothelioma, and they are currently under s
Publikováno v:
International Journal of Radiation Biology. 97:1044-1054
Traditional cancer therapy choices for clinicians are surgery, chemotherapy, radiation and immune therapy which are used either standalone therapies or in various combinations. Other physical modalities beyond ionizing radiation include photodynamic
Publikováno v:
Translational Research. 217:33-46
Tumor treating fields (TTFields) is a noninvasive physical modality of cancer therapy that applies low-intensity, intermediate frequency, and alternating electric fields to a tumor. Interference with mitosis was the first mechanism describing the eff
Publikováno v:
Neuro Oncol
Tumor Treating Fields (TTFields) as a component of cancer therapy has been shown to provide significant clinical benefit. The disruption of mitosis was identified as the first mechanism of action, however, a novel role for TTFields outside of mitosis
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e230-e231
Purpose/Objective(s) TTFields is a novel non-invasive physical modality of cancer therapy which was initially thought to interfere with cancer cell mitosis to induce cell death. Genomics and proteomic results suggested the additional mechanisms of ac
Publikováno v:
Cancer Research. 82:3316-3316
New physical cancer treatment modality called Tumor Treating Fields (TTFields) deliver low-intensity, intermediate frequency, alternating electric fields non-invasively to the tumor. TTFields is believed to inhibit mitosis as its primary mechanism of